GBG Research at SABCS Virtual Meeting 2020


GBG Research at SABCS Virtual Meeting 2020

Data on GBG study PenelopeB and several collaborative projects will be presented at the SABCS Virtual Meeting 2020.


GS1-02 Oral presentation Wednesday, December 9, 2020. General Session 1
Moderator: Angela DeMichele, MD, MSCE, Time: 8:15-8-30 AM CT
Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B
Loibl S, Marmé F, Martin M, et al.


OT-03-01, TIP, ePoster Wednesday, December 9, 2020: 8:00 AM CT
Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05)
Geyer, Jr CE, Untch M, Prat A, et al.


PD3-01, Poster discussion Spotlight Poster Discussion 3 – Wednesday, December 9, 2020: 6:30 pm – 7:45 pm CT
BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial
Krop I, Mittempergher L, Paulson J, et al.

PS7-21, ePoster Poster Session 7 – Wednesday, December 9, 2020: 8:00 AM CT
Timelines to initiate an adjuvant phase III trial across the globe: a sub-analysis of the APHINITY trial
Franzoi MA, Procter M, Emond O, et al.

PS10-01, ePoster Poster Session 10 – Wednesday, December 9, 2020: 8:00 AM CT
6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: a STEPP analysis of the APHINITY (BIG 4-11) trial
Gelber RD, Wang XV, Cole BF, et al.


GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd